全球肌肉萎縮症市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計肌肉萎縮症 (AMD) 市場將從 2025 年的 269.1 億美元成長到 2034 年的 996.8 億美元，2026 年至 2034 年的複合年成長率為 15.66%。

由於肌肉萎縮症和惡病質等疾病的盛行率不斷上升，全球肌肉萎縮症市場正穩定成長。人口老化和慢性病的發病率上升也促使人們對有效治療方法的需求增加。生物技術和基因治療研究的進步正在推動創新治療方法的開發。公眾意識的提高和診斷能力的增強進一步推動了市場擴張。

關鍵成長要素包括對罕見疾病研究投入的增加和監管激勵措施的支持。製藥公司正專注於標靶治療和個人化醫療方法。臨床試驗的擴展以及研究機構與生物技術公司之間的合作正在加速創新。此外，新興國家醫療基礎設施的改善也有助於提高患者獲得治療的機會。

展望未來，基因編輯技術和再生醫學的進步預計將對市場產生積極影響。早期診斷和支持性護理計畫的擴展有望改善患者的治療效果。罕見疾病研究經費的增加將開闢新的成長途徑。在科學不斷突破的背景下，全球肌肉萎縮症（AMD）市場預計將持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球肌肉萎縮症市場：依類型分類

• 市場分析、洞察與預測
• 肌肉萎縮症
• 肌肉萎縮

第5章 全球肌肉萎縮症市場：依治療類型分類

• 市場分析、洞察與預測
• 製藥
• 物理治療
• 營養療法
• 外科手術
• 基因治療
• 其他

第6章 全球肌肉萎縮症市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 復健設施
• 專科診所
• 其他

第7章 全球肌肉萎縮症市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Biogen
  • F. Hoffmann-La Roche
  • Novartis
  • Ionis Pharmaceuticals
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • PTC Therapeutics
  • Teva Pharmaceutical Industries
  • Regeneron Pharmaceuticals
  • Acceleron Pharma Inc

The Muscle Wasting Disorders Market size is expected to reach USD 99.68 Billion in 2034 from USD 26.91 Billion (2025) growing at a CAGR of 15.66% during 2026-2034.

The Global Muscle Wasting Disorders Market is growing steadily due to increasing prevalence of conditions such as muscular dystrophy and cachexia. Rising aging populations and higher incidence of chronic diseases are contributing to demand for effective treatment options. Advances in biotechnology and gene therapy research are supporting the development of innovative therapies. Growing awareness and improved diagnostic capabilities are further driving market expansion.

Key growth drivers include increased investment in rare disease research and supportive regulatory incentives. Pharmaceutical companies are focusing on targeted therapies and personalized medicine approaches. Expanding clinical trials and collaboration between research institutions and biotech firms are accelerating innovation. Additionally, improved healthcare infrastructure in emerging economies is enhancing access to treatment.

Looking ahead, the market is expected to benefit from advancements in gene editing and regenerative medicine. Early diagnosis and supportive care programs will improve patient outcomes. Increased funding for rare disease research will create new growth avenues. As scientific breakthroughs continue, the Global Muscle Wasting Disorders Market is projected to witness sustained development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Muscular Dystrophy
• Muscular Atrophy

By Treatment Type

• Medications
• Physical Therapy
• Nutritional Therapy
• Surgery
• Gene Therapy
• Others

By End-user

• Hospitals
• Rehab Centers
• Specialty Clinics
• Others

COMPANIES PROFILED

• Biogen, F HoffmannLa Roche, Novartis, Ionis Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku, PTC Therapeutics, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Acceleron Pharma Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Muscular Dystrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Muscular Atrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Physical Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Nutritional Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Rehab Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MUSCLE WASTING DISORDERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Treatment Type
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Treatment Type
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Treatment Type
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Treatment Type
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Treatment Type
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MUSCLE WASTING DISORDERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Biogen
  • 9.2.2 F. Hoffmann-La Roche
  • 9.2.3 Novartis
  • 9.2.4 Ionis Pharmaceuticals
  • 9.2.5 Sarepta Therapeutics
  • 9.2.6 Nippon Shinyaku
  • 9.2.7 PTC Therapeutics
  • 9.2.8 Teva Pharmaceutical Industries
  • 9.2.9 Regeneron Pharmaceuticals
  • 9.2.10 Acceleron Pharma Inc